About an article featuring Braizon Therapeutics, Inc. in the Japan Chemical Daily (published in October 16, 2019)

A recently published Japan Chemical Daily newspaper article featuring our company was entitled “Braizon: In-house development of pediatric brain tumor drugs” (translated from Japanese). However, we wish to make it clear that our primary business model is the licensing of our platform technology for drug delivery into the brain to pharmaceutical companies. Through these partnerships Braizon will contribute to the development of new drugs for CNS diseases.

Additionally, we intend to utilize our core technology to develop our own pipeline of CNS drugs in the future. At present time, we are in the selection stage for drug compound candidates for development of this pipeline. Drugs with the potential to treat pediatric brain tumors are amongst these candidates, but the final selection has not been made.

We aim to use our drug delivery technology to contribute to the development of valuable medicines for the treatment CNS diseases with pharmaceutical companies worldwide.

Thank you for your understanding and continued support.

Source article: Japan Chemical Daily “ Children’s brain tumor drug developed in-house-DDS application to known anticancer drugs ” (October 16, 2019)